Diffusion Pharmaceuticals (NASDAQ:DFFN) and BIOLINERX Ltd/S (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Institutional and Insider Ownership

7.6% of Diffusion Pharmaceuticals shares are held by institutional investors. Comparatively, 34.7% of BIOLINERX Ltd/S shares are held by institutional investors. 5.8% of Diffusion Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of BIOLINERX Ltd/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Diffusion Pharmaceuticals has a beta of -1.93, meaning that its share price is 293% less volatile than the S&P 500. Comparatively, BIOLINERX Ltd/S has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Diffusion Pharmaceuticals and BIOLINERX Ltd/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diffusion Pharmaceuticals 0 0 1 0 3.00
BIOLINERX Ltd/S 0 1 3 0 2.75

Diffusion Pharmaceuticals presently has a consensus price target of $1.25, indicating a potential upside of 252.41%. BIOLINERX Ltd/S has a consensus price target of $3.00, indicating a potential upside of 309.11%. Given BIOLINERX Ltd/S’s higher probable upside, analysts clearly believe BIOLINERX Ltd/S is more favorable than Diffusion Pharmaceuticals.

Earnings & Valuation

This table compares Diffusion Pharmaceuticals and BIOLINERX Ltd/S’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Diffusion Pharmaceuticals N/A N/A -$1.36 million ($1.14) -0.31
BIOLINERX Ltd/S N/A N/A -$24.35 million ($0.27) -2.72

BIOLINERX Ltd/S is trading at a lower price-to-earnings ratio than Diffusion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Diffusion Pharmaceuticals and BIOLINERX Ltd/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Diffusion Pharmaceuticals N/A -36.05% -25.90%
BIOLINERX Ltd/S N/A -49.42% -43.48%

Summary

Diffusion Pharmaceuticals beats BIOLINERX Ltd/S on 6 of the 11 factors compared between the two stocks.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.

About BIOLINERX Ltd/S

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company’s other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech’s Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi’in, Israel.



Receive News & Ratings for Diffusion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *